“What we are trying to do is inhibit this pathway so there will be no more signaling,” said Dr. Shruti Sharma, vascular and endothelial biologist in the Center for Biotechnology and Genomic Medicine at the Medical College of Georgia at Augusta University. Sharma is talking about the pro-inflammatory cascade that can result when high levels of glucose in the blood prompt high circulating levels of the immune-system driver IL-6. High circulating IL-6 has been found in the blood as well as the fluid portion of the eyes of patients with diabetic retinopathy. When circulating levels of IL-6 increase, so do levels of its receptor, IL-6R, which is required for IL-6 to be active. These floating inflammation drivers enable something called trans-signaling – where receptors aren’t directly found on the affected cells themselves – and there is emerging evidence from Sharma’s lab and others that it’s a major player in inflammation-driven diseases like diabetic retinopathy, inflammatory bowel disease, even atherosclerosis. In this case, the body appears to have a check system: Sgp130 also is traveling in the bloodstream where it can essentially trap the IL-6/IL-6 receptor complex and keep it from crossing cell membranes to promote inflammation. However, in the altered face of diabetes, apparently its action is not always sufficient. That’s why Sharma’s new $1.5 million grant from the National Eye Institute is enabling the first attempt to target IL-6 trans-signaling in diabetic retinopathy with this synthetic, more powerful version of sgp130, called sgp130-Fc, which is already in clinical trials for Crohn’s disease and rheumatoid arthritis. The MCG research team hopes its work in human serum and mouse models will lead to clinical trials of sgp130-Fc in diabetic retinopathy as well.
For the original version including any supplementary images or video, visit https://www.eurekalert.org/pub_releases/2017-01/mcog-pam010317.php
Transient loss of vision may precede Retinal Artery Occlusion. http://advisingeyesurgeon.beatthetrain.org/2016/12/05/the-top-information-on-choosing-critical-criteria-of-eye-bags/Bleeding from abnormal retinal blood vessels can cause the appearance of “floating” spots. This treatment is also used for some kinds of glaucoma. Retinal vascular disease such as retinal vein or artery occlusion. There are three main types of diabetic retinopathy: Non-proliferative retinopathy is an early form of the disease, where the retinal blood vessels leak fluid or bleed. Although retinopathy does not usually cause vision loss at this stage, the capillary walls may lose their ability to control the passage of substances between the blood and the retina. At this advanced stage, growth factors secreted by the retina trigger the proliferation of new blood vessels, which grow along the inside surface of the retina and into the vitreous gel, the fluid that fills the eye. Unless your retina is damaged, your vision may return to its previous clarity.
Side effects of scatter photo coagulation are usually minor. Drops may be applied to the eye to reduce inflammation and the risk of infection. People with early diabetic retinopathy may not need treatment. http://advisingeyesurgeon.beatthetrain.org/2016/12/05/the-top-information-on-choosing-critical-criteria-of-eye-bags/If you have mild or moderate non proliferative diabetic retinopathy, you may not need treatment right away. However, as the condition progresses, symptoms include: sudden loss of vision in one or both eyes Diabetic retinopathy is a long-term complication of diabetes. The bleeding haemorrhage causes scar tissue that starts to shrink and pull on the retina, leading to it becoming detached and possibly causing vision loss or blindness. It may be discovered during a routine eye exam. The eye is a ball covered with a tough outer membrane. A was developed by astronomers seeking to improve the resolution of their telescopes by filtering out distortions in the atmosphere. For decades, PDP has been treated with scatter laser surgery, sometimes called pan retinal laser surgery or pan retinal photo coagulation.